![[ Visit WOCN Website ]](images/banner09.jpg)
Goals and Objectives
The goal of our trial of this novel product was to determine the effects of Leptospermum honey on a wide variety of wound types. Specific data collected to determine the effectiveness of this product was wound measurements, report of pain, wound bed status and exudates levels.
Purpose
A new calcium alginate dressing containing active Leptospermum honey* was FDA cleared in July of 2007. There is strong clinical evidence to support the use of honey in wound management. Seventeen randomized control trials have been completed on nearly 2000 patients and many other clinical trials and case reports have been presented in the literature. Because of this evidence and the continuous challenge to heal patients with chronic non-healing wounds despite the plethora of wound products currently available on the market, it was decided to try this product in our wound program.
Methods
Four patients with chronic wounds were selected for the trial. The etiology of these wounds was either surgical, pressure, venous or traumatic in nature which well represented our treatment population.
Results
All patients showed marked improvement in wound bed status, management of exudate, decrease in wound size and atraumatic dressing changes with minimal pain.
Discussion / Conclusion
The use of Leptospermum honey was associated with excellent wound healing outcomes as well as patient and clinician satisfaction. Our experience shows a wide variety of patients can benefit from the use of active Leptospermum honey calcium alginate dressings in the both the inpatient and outpatient settings.
The goal of our trial of this novel product was to determine the effects of Leptospermum honey on a wide variety of wound types. Specific data collected to determine the effectiveness of this product was wound measurements, report of pain, wound bed status and exudates levels.
Purpose
A new calcium alginate dressing containing active Leptospermum honey* was FDA cleared in July of 2007. There is strong clinical evidence to support the use of honey in wound management. Seventeen randomized control trials have been completed on nearly 2000 patients and many other clinical trials and case reports have been presented in the literature. Because of this evidence and the continuous challenge to heal patients with chronic non-healing wounds despite the plethora of wound products currently available on the market, it was decided to try this product in our wound program.
Methods
Four patients with chronic wounds were selected for the trial. The etiology of these wounds was either surgical, pressure, venous or traumatic in nature which well represented our treatment population.
Results
All patients showed marked improvement in wound bed status, management of exudate, decrease in wound size and atraumatic dressing changes with minimal pain.
Discussion / Conclusion
The use of Leptospermum honey was associated with excellent wound healing outcomes as well as patient and clinician satisfaction. Our experience shows a wide variety of patients can benefit from the use of active Leptospermum honey calcium alginate dressings in the both the inpatient and outpatient settings.